Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2019-03-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
2018年度募集资金存放和实际使用专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2018 Annual Report on the Deposit and Actual Use of Raised Funds" by Zhengzhou Antu Biological Engineering Co., Ltd. It details the management, storage, and actual use of funds raised through an IPO, including specific investment projects, cash management, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange related to the management and use of raised funds. It includes detailed financial figures and tables about the raised funds, their usage, and investment returns. The content is focused on the use and management of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). The document is over 7,000 characters and contains substantive financial data and analysis about the raised funds, not merely an announcement or certification. Therefore, it is not a report publication announcement or regulatory filing. It is not an annual report (10-K) or interim report (IR) as it focuses specifically on the raised funds usage rather than full financial performance. Hence, the best fitting classification is Capital/Financing Update (CAP).
2019-03-27 Chinese
关于聘任公司高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the appointment of a senior management personnel, specifically the appointment of Mr. Fu Guangyu as the company's Executive Vice General Manager. It includes details about the board meeting, the nomination and approval process, and a detailed resume of the appointed individual. There is no financial data, no mention of annual or quarterly reports, no voting results, and no other regulatory filings. The content clearly fits the category of announcing changes in senior management.
2019-03-27 Chinese
关于召开2018年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2018 Annual General Meeting (AGM) of Zhengzhou Antu Bioengineering Co., Ltd., including details about the meeting date, voting procedures, agenda items, and proxy authorization. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 3540 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2019-03-27 Chinese
招商证券关于安图生物2018年度募集资金的存放与使用情况之专项核查报告
Regulatory Filings
2019-03-27 Chinese
前次募集资金使用情况鉴证报告
Regulatory Filings
2019-03-27 Chinese
第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the third board of directors of Zhengzhou Antu Bioengineering Co., Ltd. It includes voting results on various reports and proposals such as the 2018 annual general manager work report, board work report, independent directors' reports, financial statements, profit distribution plan, appointment of auditors, internal control evaluation, loan applications, guarantees, and changes in senior management and company statutes. The document repeatedly states that these resolutions need to be submitted to the 2018 annual shareholders' meeting for approval. The document is not the annual report itself but a board meeting resolution announcement. It contains detailed board decisions and voting results, which fits the category of Board/Management Information (MANG). The document length is 3542 characters, which is relatively short but contains substantive content about board decisions rather than just a brief announcement or a certification. Therefore, the best classification is MANG (Board/Management Information).
2019-03-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.